Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.76
- Piotroski Score 2.00
- Grade Buy
- Symbol (EVO)
- Company Evotec SE
- Price $4.25
- Changes Percentage (9.96%)
- Change $0.39
- Day Low $4.19
- Day High $4.28
- Year High $12.00
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
- Last Earnings N/A
- Ex-Dividend for 5/16 Dividend 01/11/2019
- Dividend Payable N/A
- Today N/A
- Next Earnings (Estimated) 03/27/2025
- Fiscal Year End N/A
- Average Stock Price Target $8.00
- High Stock Price Target $8.00
- Low Stock Price Target $8.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.28
- Trailing P/E Ratio -17.07
- Forward P/E Ratio -17.07
- P/E Growth -17.07
- Net Income $-83,913,000
Income Statement
Quarterly
Annual
Latest News of EVO
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Evonik Industries (ETR:EVK) Has More To Do To Multiply In Value Going Forward
To identify stocks with long-term growth potential, look for increasing Return on Capital Employed (ROCE) and capital employed. Evonik Industries (ETR:EVK) has a low ROCE of 5.5%, indicating limited r...
By Yahoo! Finance | 1 day ago -
Decoding Devon Energy Corp (DVN): A Strategic SWOT Insight
Devon Energy Corp, a key player in the oil and gas industry, reported strong financials in its 10-Q filing, boasting robust production and reserves, strategic acquisitions, and financial resilience. H...
By Yahoo! Finance | 1 day ago -
Democrats' huge mistake, revolt of the working class and other...
Donald Trump's victory in 2024 is attributed to the electorate's rejection of the Biden-Harris administration. Democrats' shift leftward and failure to connect with working-class voters led to their d...
By New York Post | 1 day ago
